{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:06:33Z","timestamp":1773212793723,"version":"3.50.1"},"reference-count":121,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FCT-Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["UIDP\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020"]}]},{"name":"FCT-Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDB\/04378\/2020"]}]},{"name":"FCT-Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["LA\/P\/0140\/2020"],"award-info":[{"award-number":["LA\/P\/0140\/2020"]}]},{"name":"Associate Laboratory Institute for Health and Bioeconomy\u2013i4HB","award":["UIDP\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020"]}]},{"name":"Associate Laboratory Institute for Health and Bioeconomy\u2013i4HB","award":["UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDB\/04378\/2020"]}]},{"name":"Associate Laboratory Institute for Health and Bioeconomy\u2013i4HB","award":["LA\/P\/0140\/2020"],"award-info":[{"award-number":["LA\/P\/0140\/2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Bladder cancer (BC) stands as one of the most prevalent urological malignancies, with over 500 thousand newly diagnosed cases annually. Treatment decisions in BC depend on factors like the risk of recurrence, the type of tumor, and the stage of the disease. While standard therapeutic approaches encompass transurethral resection of the bladder tumor, radical cystectomy, and chemo- or immunotherapy, these methods exhibit limited efficacy in mitigating the aggressive and recurrent nature of bladder tumors. To overcome this challenge, it is crucial to develop innovative methods for monitoring and predicting treatment responses among patients with BC. Metabolomics is gaining recognition as a promising approach for discovering biomarkers. It has the potential to reveal metabolic disruptions that precisely reflect how BC patients respond to particular treatments, providing a revolutionary method to improve accuracy in monitoring and predicting outcomes. In this article, we present a comprehensive review of studies employing metabolomics approaches to investigate the metabolic responses associated with different treatment modalities for BC. The review encompasses an exploration of various models, samples, and analytical techniques applied in this context. Special emphasis is placed on the reported changes in metabolite levels derived from these studies, highlighting their potential as biomarkers for personalized medicine in BC.<\/jats:p>","DOI":"10.3390\/ijms242417543","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T03:59:24Z","timestamp":1702871964000},"page":"17543","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Metabolomic Signatures of Treatment Response in Bladder Cancer"],"prefix":"10.3390","volume":"24","author":[{"given":"Tiago","family":"Vieira de Sousa","sequence":"first","affiliation":[{"name":"Associate Laboratory i4HB\u2013Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal"},{"name":"UCIBIO\u2013Applied Molecular Biosciences Unit, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7395-5700","authenticated-orcid":false,"given":"Paula","family":"Guedes de Pinho","sequence":"additional","affiliation":[{"name":"Associate Laboratory i4HB\u2013Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal"},{"name":"UCIBIO\u2013Applied Molecular Biosciences Unit, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9719-8364","authenticated-orcid":false,"given":"Joana","family":"Pinto","sequence":"additional","affiliation":[{"name":"Associate Laboratory i4HB\u2013Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal"},{"name":"UCIBIO\u2013Applied Molecular Biosciences Unit, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Hasin, Y., Seldin, M., and Lusis, A. (2017). Multi-omics approaches to disease. Genome Biol., 18.","DOI":"10.1186\/s13059-017-1215-1"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3322\/caac.21670","article-title":"Metabolomics in cancer research and emerging applications in clinical oncology","volume":"71","author":"Schmidt","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1080\/004982599238047","article-title":"\u2018Metabonomics\u2019: Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data","volume":"29","author":"Nicholson","year":"1999","journal-title":"Xenobiotica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1013713905833","article-title":"Metabolomics--the link between genotypes and phenotypes","volume":"48","author":"Fiehn","year":"2002","journal-title":"Plant Mol. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Li, B., He, X., Jia, W., and Li, H. (2017). Novel Applications of Metabolomics in Personalized Medicine: A Mini-Review. Molecules, 22.","DOI":"10.3390\/molecules22071173"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40200-021-00824-0","article-title":"The importance of personalized medicine in urological cancers","volume":"21","author":"Khatami","year":"2022","journal-title":"J. Diabetes Metab. Disord."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1007\/s11033-022-07571-2","article-title":"Breast cancer in the era of precision medicine","volume":"49","author":"Sarhangi","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lavallee, E., Sfakianos, J.P., and Mulholland, D.J. (2021). Tumor Heterogeneity and Consequences for Bladder Cancer Treatment. Cancers, 13.","DOI":"10.3390\/cancers13215297"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11912-018-0727-5","article-title":"Molecular Subtypes of Bladder Cancer","volume":"20","author":"McConkey","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ferro, M., La Civita, E., Liotti, A., Cennamo, M., Tortora, F., Buonerba, C., Crocetto, F., Lucarelli, G., Busetto, G.M., and Del Giudice, F. (2021). Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer. J. Pers. Med., 11.","DOI":"10.3390\/jpm11030237"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102530","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: Treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/jclinpath-2018-205356","article-title":"CDK12: An emerging therapeutic target for cancer","volume":"71","author":"Lui","year":"2018","journal-title":"J. Clin. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zhou, J., and Zhong, L. (2022). Applications of liquid chromatography-mass spectrometry based metabolomics in predictive and personalized medicine. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.1049016"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/s41598-018-19199-z","article-title":"The global epidemiology of bladder cancer: A joinpoint regression analysis of its incidence and mortality trends and projection","volume":"8","author":"Wong","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and Risk Factors of Urothelial Bladder Cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: An update","volume":"38","author":"Richters","year":"2020","journal-title":"World J. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","article-title":"Epidemiology, Screening, and Prevention of Bladder Cancer","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_20","unstructured":"(2023, November 20). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.fr\/today\/fact-sheets-cancers."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/MOU.0000000000000086","article-title":"Impact of histological variants on the outcomes of nonmuscle invasive bladder cancer after transurethral resection","volume":"24","author":"Seisen","year":"2014","journal-title":"Curr. Opin. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.21037\/tcr-20-2169","article-title":"Variant histology in bladder cancer: Diagnostic and clinical implications","volume":"9","author":"Black","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder Cancer: A Review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA A Cancer J. Clin."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: Epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrurol.2009.236","article-title":"Molecular screening for bladder cancer: Progress and potential","volume":"7","author":"Mitra","year":"2010","journal-title":"Nat. Rev. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non\u2013muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: Long-term follow-up of a phase 2 study","volume":"23","author":"Necchi","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: A narrative review of diagnostics and treatments","volume":"400","author":"Amin","year":"2022","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Jeong, S.H., and Ku, J.H. (2022). Urinary Markers for Bladder Cancer Diagnosis and Monitoring. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.892067"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.7150\/jca.28989","article-title":"A review on the accuracy of bladder cancer detection methods","volume":"10","author":"Zhu","year":"2019","journal-title":"J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Oeyen, E., Hoekx, L., De Wachter, S., Baldewijns, M., Ameye, F., and Mertens, I. (2019). Bladder Cancer Diagnosis and Follow-Up: The Current Status and Possible Role of Extracellular Vesicles. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040821"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Abouelkheir, R.T., Abdelhamid, A., Abou El-Ghar, M., and El-Diasty, T. (2021). Imaging of Bladder Cancer: Standard Applications and Future Trends. Medicina, 57.","DOI":"10.3390\/medicina57030220"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.euo.2022.04.008","article-title":"Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations","volume":"5","author":"Patrick","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Galgano, S.J., Porter, K.K., Burgan, C., and Rais-Bahrami, S. (2020). The Role of Imaging in Bladder Cancer Diagnosis and Staging. Diagnostics, 10.","DOI":"10.3390\/diagnostics10090703"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1002\/cam4.1979","article-title":"Hope and challenge: Precision medicine in bladder cancer","volume":"8","author":"Su","year":"2019","journal-title":"Cancer Med."},{"key":"ref_40","first-page":"507","article-title":"Bladder Cancer: Diagnosis and Treatment","volume":"96","author":"Degeorge","year":"2017","journal-title":"Am. Fam. Physician"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Mancini, M., Righetto, M., Zumerle, S., Montopoli, M., and Zattoni, F. (2020). The Bladder EpiCheck Test as a Non-Invasive Tool Based on the Identification of DNA Methylation in Bladder Cancer Cells in the Urine: A Review of Published Evidence. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186542"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.urolonc.2007.06.002","article-title":"UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testing","volume":"26","author":"Hajdinjak","year":"2008","journal-title":"Urol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/S0022-5347(01)65569-1","article-title":"Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract","volume":"156","author":"Carpinito","year":"1996","journal-title":"J. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00345-012-0935-9","article-title":"Urinary BTA: Indicator of bladder cancer or of hematuria","volume":"30","author":"Miyake","year":"2012","journal-title":"World J. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S546","DOI":"10.21037\/tau.2019.12.41","article-title":"UroSEEK gene panel for bladder cancer surveillance","volume":"8","author":"Wong","year":"2019","journal-title":"Transl. Androl. Urol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.juro.2017.09.141","article-title":"Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection","volume":"199","author":"Ellen","year":"2018","journal-title":"J. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Koya, M., Osborne, S., Chemasl\u00e9, C., Porten, S., Schuckman, A., and Kennedy-Smith, A. (2020). An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer. BMC Urol., 20.","DOI":"10.1186\/s12894-020-0583-0"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00345-018-2380-x","article-title":"An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer","volume":"36","author":"Soria","year":"2018","journal-title":"World J. Urol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.juro.2014.09.092","article-title":"Clinical Outcomes of cT1 Micropapillary Bladder Cancer","volume":"193","author":"Willis","year":"2015","journal-title":"J. Urol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bju.14417","article-title":"A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens","volume":"123","author":"Mari","year":"2019","journal-title":"BJU Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1102392","DOI":"10.3389\/fonc.2022.1102392","article-title":"Label-free LC-MS\/MS proteomics analyses reveal CLIC1 as a predictive biomarker for bladder cancer staging and prognosis","volume":"12","author":"Wang","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3390\/medicina57080749","article-title":"Bladder Cancer: Current Challenges and Future Directions","volume":"57","author":"Dobruch","year":"2021","journal-title":"Medicina"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.21037\/tau.2019.09.38","article-title":"Transurethral resection of bladder tumour (TURBT)","volume":"9","author":"Kim","year":"2020","journal-title":"Transl. Androl. Urol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/MOU.0000000000000746","article-title":"Novel technologies that change the diagnostic and treatment paradigm in urology","volume":"30","author":"Lotan","year":"2020","journal-title":"Curr. Opin. Urol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4103\/iju.IJU_218_17","article-title":"Utility of restage transurethral resection of bladder tumor","volume":"34","author":"Manoharan","year":"2018","journal-title":"Indian. J. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.juro.2013.08.022","article-title":"The Effect of Restaging Transurethral Resection on Recurrence and Progression Rates in Patients with Nonmuscle Invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-Gu\u00e9rin","volume":"191","author":"Sfakianos","year":"2014","journal-title":"J. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1100\/tsw.2011.29","article-title":"Role of Re-Resection in Non\u2013Muscle-Invasive Bladder Cancer","volume":"11","author":"Herr","year":"2011","journal-title":"Sci. World J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.euf.2017.08.005","article-title":"Comparative Perioperative Outcomes in Septuagenarians and Octogenarians Undergoing Radical Cystectomy for Bladder Cancer\u2014Do Outcomes Differ?","volume":"4","author":"Haden","year":"2018","journal-title":"Eur. Urol. Focus"},{"key":"ref_60","first-page":"293","article-title":"Robotic radical cystectomy","volume":"72","author":"Gaya","year":"2019","journal-title":"Arch. Esp. Urol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"110393","DOI":"10.1016\/j.biopha.2020.110393","article-title":"Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect","volume":"129","author":"Han","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1245\/s10434-018-6610-7","article-title":"Cancer Immune Therapy: Prognostic Significance and Implications for Therapy of PD-1 in BCG-Relapsing Bladder Cancer","volume":"25","author":"Mukherjee","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00345-020-03474-8","article-title":"Immunotherapy in non-muscle-invasive bladder cancer: Current status and future directions","volume":"39","author":"Pfail","year":"2021","journal-title":"World J. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00345-018-2591-1","article-title":"Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: How, when and what","volume":"37","author":"Peyton","year":"2019","journal-title":"World J. Urol."},{"key":"ref_65","first-page":"35.e21","article-title":"Interferon alfa in the treatment paradigm for non\u2013muscle-invasive bladder cancer","volume":"32","author":"Lamm","year":"2014","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","article-title":"Sequential Combination of Mitomycin C Plus Bacillus Calmette-Gu\u00e9rin (BCG) Is More Effective but More Toxic Than BCG Alone in Patients with Non\u2013Muscle-invasive Bladder Cancer in Intermediate- and High-risk Patients: Final Outcome of CUETO 93009, a Randomized Prospective Trial","volume":"67","author":"Solsona","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2016.03.034","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin Versus Combination of Epirubicin and Interferon-\u03b12a in Reducing Recurrence of Non\u2013Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study","volume":"70","author":"Marttila","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","article-title":"Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa\u2013pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00345-021-03908-x","article-title":"Adjuvant therapies for non-muscle-invasive bladder cancer: Advances during BCG shortage","volume":"40","author":"Balasubramanian","year":"2022","journal-title":"World J. Urol."},{"key":"ref_70","first-page":"CD009294","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"2021","author":"Han","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e230849","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Gu\u00e9rin for the Treatment of Patients With High-Risk Non\u2013Muscle-Invasive Bladder Cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_72","first-page":"901","article-title":"Early Experience with Intravesical Gemcitabine-Docetaxel for BCG-Na\u00efve Patients with High Grade Non-Muscle Invasive Bladder Cancer","volume":"38","author":"Babajide","year":"2020","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_73","first-page":"35.e15","article-title":"Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non\u2013muscle invasive bladder cancer","volume":"32","author":"Lightfoot","year":"2014","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5301\/uj.5000230","article-title":"Systemic Chemotherapy in Muscle Invasive and Metastatic Bladder Cancer: Present and Future","volume":"84","author":"Sternberg","year":"2017","journal-title":"Urol. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3892\/ol.2023.13851","article-title":"Metabolic biomarkers in lung cancer screening and early diagnosis (Review)","volume":"25","author":"Xu","year":"2023","journal-title":"Oncol. Lett."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Neagu, A.N., Whitham, D., Bruno, P., Morrissiey, H., Darie, C.A., and Darie, C.C. (2023). Omics-Based Investigations of Breast Cancer. Molecules, 28.","DOI":"10.3390\/molecules28124768"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"125296","DOI":"10.1016\/j.talanta.2023.125296","article-title":"Exploiting volatile fingerprints for bladder cancer diagnosis: A scoping review of metabolomics and sensor-based approaches","volume":"268","author":"Carapito","year":"2024","journal-title":"Talanta"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Lima, A.R., Pinto, J., Amaro, F., Bastos, M.L., Carvalho, M., and Guedes de Pinho, P. (2021). Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics. Metabolites, 11.","DOI":"10.3390\/metabo11030181"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/metabo7040060","article-title":"Monitoring for Response to Antineoplastic Drugs: The Potential of a Metabolomic Approach","volume":"7","author":"Rattner","year":"2017","journal-title":"Metabolites"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41580-019-0108-4","article-title":"Identification of bioactive metabolites using activity metabolomics","volume":"20","author":"Rinschen","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Alonso, A., Marsal, S., and Juli\u00e0, A. (2015). Analytical methods in untargeted metabolomics: State of the art in 2015. Front. Bioeng. Biotechnol., 3.","DOI":"10.3389\/fbioe.2015.00023"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1002\/anie.200905579","article-title":"Targeted metabolomics for biomarker discovery","volume":"49","author":"Griffiths","year":"2010","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ijc.30016","article-title":"Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems","volume":"139","author":"Rodrigues","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrm.2016.25","article-title":"Metabolomics: Beyond biomarkers and towards mechanisms","volume":"17","author":"Johnson","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.4155\/bio.12.204","article-title":"The importance of experimental design and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans","volume":"4","author":"Dunn","year":"2012","journal-title":"Bioanalysis"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.aca.2016.02.001","article-title":"Chemometric methods in data processing of mass spectrometry-based metabolomics: A review","volume":"914","author":"Yi","year":"2016","journal-title":"Anal. Chim. Acta"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11306-018-1460-7","article-title":"Towards quality assurance and quality control in untargeted metabolomics studies","volume":"15","author":"Beger","year":"2019","journal-title":"Metabolomics"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cbpa.2017.01.001","article-title":"How close are we to complete annotation of metabolomes?","volume":"36","author":"Viant","year":"2017","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_90","first-page":"12","article-title":"Methods of Metabolite Identification Using MS\/MS Data","volume":"62","author":"Kwak","year":"2022","journal-title":"J. Comput. Inf. Syst."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11306-007-0082-2","article-title":"Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI)","volume":"3","author":"Sumner","year":"2007","journal-title":"Metabolomics"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"di Meo, N.A., Loizzo, D., Pandolfo, S.D., Autorino, R., Ferro, M., Porta, C., Stella, A., Bizzoca, C., Vincenti, L., and Crocetto, F. (2022). Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084173"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cca.2013.08.020","article-title":"The role of metabolomics in neonatal and pediatric laboratory medicine","volume":"426","author":"Michele","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.aca.2015.02.012","article-title":"A tutorial review: Metabolomics and partial least squares-discriminant analysis\u2014A marriage of convenience or a shotgun wedding","volume":"879","author":"Piotr","year":"2015","journal-title":"Anal. Chim. Acta"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Debik, J., Sangermani, M., Wang, F., Madssen, T.S., and Giske\u00f8deg\u00e5rd, G.F. (2022). Multivariate analysis of NMR-based metabolomic data. NMR Biomed., 35.","DOI":"10.1002\/nbm.4638"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11306-007-0099-6","article-title":"Assessment of PLSDA cross validation","volume":"4","author":"Westerhuis","year":"2008","journal-title":"Metabolomics"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11306-011-0330-3","article-title":"Double-check: Validation of diagnostic statistics for PLS-DA models in metabolomics studies","volume":"8","author":"Saccenti","year":"2012","journal-title":"Metabolomics"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/metabo12040357","article-title":"Guide to Metabolomics Analysis: A Bioinformatics Workflow","volume":"12","author":"Chen","year":"2022","journal-title":"Metabolites"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s11306-012-0482-9","article-title":"Translational biomarker discovery in clinical metabolomics: An introductory tutorial","volume":"9","author":"Xia","year":"2013","journal-title":"Metabolomics"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Tsouka, S., and Masoodi, M. (2023). Metabolic Pathway Analysis: Advantages and Pitfalls for the Functional Interpretation of Metabolomics and Lipidomics Data. Biomolecules, 13.","DOI":"10.3390\/biom13020244"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3390\/ph15030295","article-title":"Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers","volume":"15","author":"Amaro","year":"2022","journal-title":"Pharmaceuticals"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1158\/1078-0432.CCR-18-1515","article-title":"Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer","volume":"25","author":"Vantaku","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0079-6603(01)67026-0","article-title":"Cisplatin: From DNA damage to cancer chemotherapy","volume":"67","author":"Cohen","year":"2001","journal-title":"Prog. Nucleic Acid. Res. Mol. Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00345-018-2544-8","article-title":"Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: Are we understanding how, who and when?","volume":"37","author":"Schardt","year":"2019","journal-title":"World J. Urol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.bbalip.2018.06.005","article-title":"Glucose-derived acetate and ACSS2 as key players in cisplatin resistance in bladder cancer","volume":"1864","author":"Wen","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"13231","DOI":"10.18632\/oncotarget.24229","article-title":"Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance","volume":"9","author":"Lee","year":"2018","journal-title":"Oncotarget"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ygeno.2021.11.028","article-title":"The potential role of c-MYC and polyamine metabolism in multiple drug resistance in bladder cancer investigated by metabonomics","volume":"114","author":"Zhu","year":"2022","journal-title":"Genomics"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.cbi.2015.09.005","article-title":"Lipidomics: Novel insight into the biochemical mechanism of lipid metabolism and dysregulation-associated disease","volume":"240","author":"Zhao","year":"2015","journal-title":"Chem. Biol. Interact."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/iub.230","article-title":"Mammalian polyamine metabolism and function","volume":"61","author":"Pegg","year":"2009","journal-title":"IUBMB Life"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1101\/cshperspect.a014241","article-title":"MYC activation is a hallmark of cancer initiation and maintenance","volume":"4","author":"Gabay","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ccell.2020.12.002","article-title":"An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence","volume":"39","author":"Dhimolea","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.semcancer.2014.06.002","article-title":"Crosstalk between DNA repair and cancer stem cell (CSC) associated intracellular pathways","volume":"31","author":"Sergej","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"113134","DOI":"10.1016\/j.jpba.2020.113134","article-title":"NMR-derived targeted serum metabolic biomarkers appraisal of bladder cancer: A pre- and post-operative evaluation","volume":"183","author":"Gupta","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.3390\/cancers14051210","article-title":"Pre- and Post-Resection Urine Metabolic Profiles of Bladder Cancer Patients: Results of Preliminary Studies on Time Series Metabolomics Analysis","volume":"14","author":"Jacyna","year":"2022","journal-title":"Cancers"},{"key":"ref_115","first-page":"1952","article-title":"Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine","volume":"44","author":"Yang","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/metabo12060558","article-title":"Metabolic Profiling of Bladder Cancer Patients\u2019 Serum Reveals Their Sensitivity to Neoadjuvant Chemotherapy","volume":"12","author":"Zhuang","year":"2022","journal-title":"Metabolites"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1021\/pr400859w","article-title":"Low- and High-Grade Bladder Cancer Determination via Human Serum-Based Metabolomics Approach","volume":"12","author":"Bansal","year":"2013","journal-title":"J. Proteome Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.talanta.2019.05.039","article-title":"Urinary metabolomic signature of muscle-invasive bladder cancer: A multiplatform approach","volume":"202","author":"Jacyna","year":"2019","journal-title":"Talanta"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3389\/fimmu.2018.01697","article-title":"Potential Mechanisms Connecting Purine Metabolism and Cancer Therapy","volume":"9","author":"Yin","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"13349","DOI":"10.18632\/aging.202962","article-title":"Emerging roles of nucleotide metabolism in cancer development: Progress and prospect","volume":"13","author":"Ma","year":"2021","journal-title":"Aging"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrurol.2013.89","article-title":"DNA methylation-based biomarkers in bladder cancer","volume":"10","author":"Kandimalla","year":"2013","journal-title":"Nat. Rev. Urol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/24\/17543\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:40:00Z","timestamp":1760132400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/24\/17543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,16]]},"references-count":121,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["ijms242417543"],"URL":"https:\/\/doi.org\/10.3390\/ijms242417543","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,16]]}}}